Trial of Antihypertensive Intervention Management
Information source: National Heart, Lung, and Blood Institute (NHLBI)
Information obtained from ClinicalTrials.gov on June 20, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cardiovascular Diseases; Heart Diseases; Hypertension; Vascular Diseases
Intervention: diet, reducing (Behavioral); diet, sodium-restricted (Behavioral); chlorthalidone (Drug); atenolol (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: National Heart, Lung, and Blood Institute (NHLBI) Official(s) and/or principal investigator(s): Morton Blaufox, Affiliation: Albert Einstein College of Medicine of Yeshiva University Kent Kirchner, Affiliation: University of Mississippi Medical Center Albert Oberman, Affiliation: University of Alabama at Birmingham Sylvia Wassertheil-Smoller, Affiliation: Albert Einstein College of Medicine of Yeshiva University
Summary
The objective of the Trial of Antihypertensive Intervention Management (TAIM) was to
determine the efficacy of dietary management and/or drug therapy, namely thiazide-like
diuretics or a beta-blocker, in the control of mild hypertension. Additionally, the
Continuation of the Trial of Antihypertensive Intervention Management (COTAIM) tested the
effects of long-term weight reduction, and sodium/potassium changes added to weight
reduction, as well as the original drug treatment, on the failure rate of blood pressure
control.
Clinical Details
Study design: Treatment, Randomized
Detailed description:
BACKGROUND:
The Trial of Antihypertensive Intervention Management was an extension of the NHLBI-supported
Dietary Intervention Study of Hypertension (DISH) which concluded in March 1984 and showed
that either weight reduction or sodium restriction diets reduced relapse rates of
hypertensives who had received long-term drug treatment and then been withdrawn from drugs.
TAIM was initiated in April 1984 and continued for four years at three centers and added to
DISH the art of evaluating combined drug and dietary treatments. COTAIM was continued at
three clinical sites in July 1988. Analysis of COTAIM results continued through November
1994 under grant R01HL40072.
DESIGN NARRATIVE:
TAIM patients were randomly assigned to one of three diets and to one of three drug regimens.
The dietary interventions consisted of a weight loss program, sodium reduction with
increased potassium intake, or no change in diet. The drug regimen consisted of a
beta-blocker (atenolol), a thiazide-like diuretic (chlorthalidone), or placebo. The major
endpoint was change in diastolic blood pressure after six months of intervention.
Individuals who did not reach goal blood pressure after six months received additional drugs.
Other endpoints included total risk factor score change, psychological function, and
lifestyle change.
COTAIM consisted of two studies with a total of 600 subjects. COTAIM I compared the TAIM
weight loss group to a randomly selected half of the usual diet group. The primary endpoint
of COTAIM I was the degree of control of blood pressure on initial TAIM therapy between TAIM
baseline and the end of COTAIM, a five year period.
COTAIM II added a weight loss regimen both to the sodium restriction/potassium
supplementation groups and to the other half of the usual diet group. The primary outcome
was control of blood pressure on initial TAIM therapy between COTAIM baseline and the end of
COTAIM, a two-year period.
Eligibility
Minimum age: 21 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Men and women, ages 21 to 65, with mild hypertension in the range of 90 to 100 mm Hg
diastolic blood pressure.
Subjects were obese (110-150 percent of ideal weight).
Locations and Contacts
Additional Information
Related publications: Davis BR, Blaufox MD, Hawkins CM, Langford HG, Oberman A, Swencionis C, Wassertheil-Smoller S, Wylie-Rosett J, Zimbaldi N. Trial of antihypertensive interventions and management. Design, methods, and selected baseline results. Control Clin Trials. 1989 Mar;10(1):11-30. Langford HG, Rockhold RW, Wassertheil-Smoller S, Oberman A, Davis BR, Blaufox MD. Effect of weight loss on thiazide produced erectile problems in men. Trans Am Clin Climatol Assoc. 1989;101:190-4. Oberman A, Wassertheil-Smoller S, Langford HG, Blaufox MD, Davis BR, Blaszkowski T, Zimbaldi N, Hawkins CM. Pharmacologic and nutritional treatment of mild hypertension: changes in cardiovascular risk status. Ann Intern Med. 1990 Jan 15;112(2):89-95. Langford HG, Davis BR, Blaufox D, Oberman A, Wassertheil-Smoller S, Hawkins M, Zimbaldi N. Effect of drug and diet treatment of mild hypertension on diastolic blood pressure. The TAIM Research Group. Hypertension. 1991 Feb;17(2):210-7. Wassertheil-Smoller S, Blaufox MD, Oberman A, Davis BR, Swencionis C, Knerr MO, Hawkins CM, Langford HG. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med. 1991 Apr 15;114(8):613-20. Langford HG. Sodium-potassium interaction in hypertension and hypertensive cardiovascular disease. Hypertension. 1991 Jan;17(1 Suppl):I155-7. Wassertheil-Smoller S, Blaufox MD, Oberman AS, Langford HG, Davis BR, Wylie-Rosett J. The Trial of Antihypertensive Interventions and Management (TAIM) study. Adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. Arch Intern Med. 1992 Jan;152(1):131-6. Davis BR, Oberman A, Blaufox MD, Wassertheil-Smoller S, Hawkins CM, Cutler JA, Zimbaldi N, Langford HG. Effect of antihypertensive therapy on weight loss. The Trial of Antihypertensive Interventions and Management Research Group. Hypertension. 1992 Apr;19(4):393-9. Wassertheil-Smoller S, Oberman A, Blaufox MD, Davis B, Langford H. The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life. Am J Hypertens. 1992 Jan;5(1):37-44. Blaufox MD, Lee HB, Davis B, Oberman A, Wassertheil-Smoller S, Langford H. Renin predicts diastolic blood pressure response to nonpharmacologic and pharmacologic therapy. JAMA. 1992 Mar 4;267(9):1221-5. Davis BR, Blaufox MD, Oberman A, Wassertheil-Smoller S, Zimbaldi N, Cutler JA, Kirchner K, Langford HG. Reduction in long-term antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild hypertension. Arch Intern Med. 1993 Aug 9;153(15):1773-82. Wylie-Rosett J, Wassertheil-Smoller S, Blaufox MD, Davis BR, Langford HG, Oberman A, Jennings S, Hataway H, Stern J, Zimbaldi N. Trial of antihypertensive intervention and management: greater efficacy with weight reduction than with a sodium-potassium intervention. J Am Diet Assoc. 1993 Apr;93(4):408-15. Davis BR, Oberman A, Blaufox MD, Wassertheil-Smoller S, Zimbaldi N, Kirchner K, Wylie-Rosett J, Langford HG. Lack of effectiveness of a low-sodium/high-potassium diet in reducing antihypertensive medication requirements in overweight persons with mild hypertension. TAIM Research Group. Trial of Antihypertensive Interventions and Management. Am J Hypertens. 1994 Oct;7(10 Pt 1):926-32. Wassertheil-Smoller S, Davis BR, Breuer B, Chang CJ, Oberman A, Blaufox MD. Differences in precision of dietary estimates among different population subgroups. Ann Epidemiol. 1993 Nov;3(6):619-28.
Starting date: April 1984
Last updated: June 23, 2005
|